IS2867B - Neublastín sem tengt er fjölliðu og aðferðir við notkun þess - Google Patents

Neublastín sem tengt er fjölliðu og aðferðir við notkun þess

Info

Publication number
IS2867B
IS2867B IS6879A IS6879A IS2867B IS 2867 B IS2867 B IS 2867B IS 6879 A IS6879 A IS 6879A IS 6879 A IS6879 A IS 6879A IS 2867 B IS2867 B IS 2867B
Authority
IS
Iceland
Prior art keywords
neublastin
methods
linked polymer
linked
polymer
Prior art date
Application number
IS6879A
Other languages
English (en)
Icelandic (is)
Other versions
IS6879A (is
Inventor
Dinah W Y Sah
R Blake Pepinsky
Paula Ann Borjack-Sjodin
Stephan S Miller
Anthony Rossomando
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of IS6879A publication Critical patent/IS6879A/is
Publication of IS2867B publication Critical patent/IS2867B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
IS6879A 2001-02-01 2003-07-17 Neublastín sem tengt er fjölliðu og aðferðir við notkun þess IS2867B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26607101P 2001-02-01 2001-02-01
PCT/US2002/002319 WO2002060929A2 (en) 2001-02-01 2002-01-25 Polymer conjugates of neublastin and methods of using same

Publications (2)

Publication Number Publication Date
IS6879A IS6879A (is) 2003-07-17
IS2867B true IS2867B (is) 2014-02-15

Family

ID=23013042

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6879A IS2867B (is) 2001-02-01 2003-07-17 Neublastín sem tengt er fjölliðu og aðferðir við notkun þess

Country Status (35)

Country Link
EP (2) EP1355936B1 (enExample)
JP (2) JP4259868B2 (enExample)
KR (2) KR100960063B1 (enExample)
CN (1) CN1500095B (enExample)
AR (1) AR035077A1 (enExample)
AT (1) ATE365748T1 (enExample)
AU (1) AU2002247037B2 (enExample)
BG (1) BG66393B1 (enExample)
BR (1) BR0206852A (enExample)
CA (1) CA2436407C (enExample)
CY (1) CY1106886T1 (enExample)
CZ (1) CZ20032080A3 (enExample)
DE (1) DE60220879T2 (enExample)
DK (1) DK1355936T3 (enExample)
EA (1) EA009771B1 (enExample)
EE (1) EE05537B1 (enExample)
ES (1) ES2289091T3 (enExample)
GE (1) GEP20063916B (enExample)
HU (1) HU228973B1 (enExample)
IL (2) IL156941A0 (enExample)
IS (1) IS2867B (enExample)
MX (1) MXPA03006805A (enExample)
MY (1) MY143685A (enExample)
NO (1) NO332150B1 (enExample)
NZ (1) NZ527863A (enExample)
PL (1) PL211162B1 (enExample)
PT (1) PT1355936E (enExample)
RS (1) RS50857B (enExample)
SG (1) SG149685A1 (enExample)
SI (1) SI1355936T1 (enExample)
SK (1) SK288123B6 (enExample)
TR (1) TR200301208T2 (enExample)
UA (2) UA100967C2 (enExample)
WO (1) WO2002060929A2 (enExample)
ZA (1) ZA200305733B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
BR0206852A (pt) * 2001-02-01 2005-05-03 Biogen Inc Conjugados de polìmero de neublastina e métodos para uso dos mesmos
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
NZ529126A (en) * 2001-03-28 2010-07-30 Biogen Idec Inc Use of neublastin polypeptides for treating allodynia, hyperalgesic pain and phantom pain
MXPA04006855A (es) * 2002-01-18 2005-04-19 Biogen Idec Inc Compuestos de polimeros de polialquileno y usos de los mismos.
SI1594436T1 (sl) 2003-01-31 2011-01-31 Biogen Idec Inc Mutirani neoblastin
ES2328640T3 (es) 2003-04-18 2009-11-16 Biogen Idec Ma Inc. Neublastina conjugada con un polimero glicosilada.
WO2004108760A2 (en) 2003-06-10 2004-12-16 Nsgene A/S Improved secretion of neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
ATE472333T1 (de) * 2004-08-19 2010-07-15 Biogen Idec Inc Rückfaltung von proteinen der transforming-growth-factor-beta-familie
UA92590C2 (uk) * 2004-08-19 2010-11-25 Байоджен Айдек Ма Інк. Варіанти нейбластину
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007103182A2 (en) * 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compostions and methods for administering gdnf ligand family proteins
CA2663300C (en) 2006-09-15 2014-10-07 Creabilis Therapeutics S.P.A. Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1
AU2008247637B2 (en) 2007-05-01 2013-12-05 Biogen Ma Inc. Compositions and methods for increasing vascularization
TR201903707T4 (tr) * 2011-11-02 2019-04-22 Hoffmann La Roche Aşırı yükleme ve elüsyon kromatografisi.
RU2488635C1 (ru) * 2012-03-22 2013-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития Способ получения рекомбинантного антиангиогенного полипептида

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472178B1 (en) * 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
EP1137774A2 (en) * 1998-12-09 2001-10-04 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
BR0206852A (pt) * 2001-02-01 2005-05-03 Biogen Inc Conjugados de polìmero de neublastina e métodos para uso dos mesmos

Also Published As

Publication number Publication date
ES2289091T3 (es) 2008-02-01
BR0206852A (pt) 2005-05-03
YU61003A (sh) 2006-05-25
SK288123B6 (sk) 2013-09-03
EP1862475A1 (en) 2007-12-05
AR035077A1 (es) 2004-04-14
PT1355936E (pt) 2007-09-28
NO20033441D0 (no) 2003-08-01
KR20080098662A (ko) 2008-11-11
DE60220879T2 (de) 2008-03-06
EA200300852A1 (ru) 2004-06-24
GEP20063916B (en) 2006-09-11
MXPA03006805A (es) 2003-11-13
KR100872807B1 (ko) 2008-12-09
IL156941A (en) 2008-11-03
CN1500095B (zh) 2010-06-16
CA2436407C (en) 2011-08-30
SK9712003A3 (en) 2004-01-08
PL211162B1 (pl) 2012-04-30
NO20033441L (no) 2003-10-01
AU2002247037B2 (en) 2007-08-16
DK1355936T3 (da) 2007-10-29
CA2436407A1 (en) 2002-08-08
UA82983C2 (ru) 2008-06-10
EA009771B1 (ru) 2008-04-28
JP4259868B2 (ja) 2009-04-30
ZA200305733B (en) 2005-02-23
WO2002060929A3 (en) 2003-03-06
JP2005503763A (ja) 2005-02-10
HK1057759A1 (en) 2004-04-16
CY1106886T1 (el) 2012-09-26
NZ527863A (en) 2006-09-29
IS6879A (is) 2003-07-17
SI1355936T1 (sl) 2007-12-31
CN1500095A (zh) 2004-05-26
HU228973B1 (en) 2013-07-29
MY143685A (en) 2011-06-30
HUP0500637A2 (hu) 2005-09-28
EP1355936A2 (en) 2003-10-29
JP4423338B2 (ja) 2010-03-03
IL156941A0 (en) 2004-02-08
ATE365748T1 (de) 2007-07-15
BG108111A (bg) 2004-12-30
UA100967C2 (ru) 2013-02-25
KR20030074766A (ko) 2003-09-19
WO2002060929A2 (en) 2002-08-08
JP2009039135A (ja) 2009-02-26
HUP0500637A3 (en) 2010-01-28
NO332150B1 (no) 2012-07-09
KR100960063B1 (ko) 2010-05-31
EE05537B1 (et) 2012-04-16
CZ20032080A3 (cs) 2003-10-15
BG66393B1 (bg) 2013-11-29
RS50857B (sr) 2010-08-31
DE60220879D1 (de) 2007-08-09
TR200301208T2 (tr) 2005-05-23
SG149685A1 (en) 2009-02-27
PL372101A1 (en) 2005-07-11
EP1355936B1 (en) 2007-06-27
EE200300355A (et) 2003-10-15

Similar Documents

Publication Publication Date Title
IS2529B (is) Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
EP1549614A4 (en) VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION
NO20041272L (no) Tetracycline derivatives and methods of use thereof
EP1298180A4 (en) HYDROPHOBIC AND LIPOPHOBE COMPOSITION
DE60207321D1 (de) Verschlussvorrichtung und -methode
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
DK1404809T3 (da) Forbedrede hudsubstitutter og anvendelser deraf
IS6656A (is) Útskiptar kínasólínafleiður og notkun þeirra sem hemla
DE60212600D1 (de) Audiocodierung und decodierung
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
IS2867B (is) Neublastín sem tengt er fjölliðu og aðferðir við notkun þess
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
IS7725A (is) Imidazólópyridín og aðferðir við framleiðslu og notkun þeirra
AU2002359512A8 (en) Belts and methods of use thereof
IS7060A (is) 2,5-díarýlpýrasín, 2,5-díarýlpýridín og 2,5-díarýlpýrimidín sem CRF1 viðtakabeinar
DE60220479D1 (de) Poloxymethylencopolymer und daraus hergestelltes formteil
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
DE60205718D1 (de) Flexibler wellschlauch und anschlussverfahren
NO20042692L (no) Sementakselerator og fremgangsmate
AU2003265231A8 (en) Molecular actuators, and methods of use thereof
NO20042693L (no) Kateterpreparat og anvendelser derav
AU2002363938A8 (en) Methods and use of motoneuronotropic factors
EP1468113A4 (en) OPTINEURINE AND GLAUCOMA
DK1441746T3 (da) Sammens tning og fremgangsmode